IGF binding proteins (IGFBPs) and regulation of breast cancer biology

Journal of Mammary Gland Biology and Neoplasia

Volumn 13, Issue 4, 2008, Pages 455-469

  Perks, Claire M ^a   Holly, Jeff M P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Breast cancer; Extracellular matrix; IGFBPs; Proteases

Indexed keywords

DROLOXIFENE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LETROZOLE; MEGESTROL ACETATE; MESSENGER RNA; OCTREOTIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; ENZYME INHIBITION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HORMONAL REGULATION; HUMAN; MODULATION; MONOTHERAPY; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION;

ANIMALS; BIOLOGY; BREAST NEOPLASMS; GLYCOSYLATION; HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; PHOSPHORYLATION;

EID: 57149142363     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10911-008-9106-4     Document Type: Article

References (181)

1. Baxter RC. IGF binding protein-3 and the acid-labile subunit: Formation of the ternary complex in vitro and in vivo. Adv Exp Med Biol. 1993;343:237-44.
2. Twigg SM, Baxter RC. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J Biol Chem. 1998;273(11):6074-9. doi: 10.1074/jbc.273.11.6074.
3. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem. 1993;52(2):196-205. doi: 10.1002/jcb.240520211.
4. Chen JC, Shao ZM, Sheikh MS, Hussain A, LeRoith D, Roberts CT Jr, et al. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol. 1994;158(1):69-78. doi: 10.1002/jcp.1041580110.
5. Ritvos O, Ranta T, Jalkanen J, Suikkari AM, Voutilainen R, Bohn H, et al. Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology. 1988;122(5):2150-7.
6. Yee D, Favoni RE, Lippman ME, Powell DR. Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res Treat. 1991;18(1):3-10. doi: 10.1007/BF01975437.
7. Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology. 1990;127(6):2679-86.
8. Sheikh MS, Shao ZM, Clemmons DR, LeRoith D, Roberts CT Jr, Fontana JA. Identification of the insulin-like growth factor binding proteins 5 and 6 (IGFBP-5 and 6) in human breast cancer cells. Biochem Biophys Res Commun. 1992;183(3):1003-10. doi: 10.1016/S0006-291X(05)80290-6.
9. Pekonen F, Nyman T, Ilvesmaki V, Partanen S. Insulin-like growth factor binding proteins in human breast cancer tissue. Cancer Res. 1992;52(19):5204-7.
10. Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV, et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997;3(1):103-9.
11. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: Detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 1996;88(9):601-6. doi: 10.1093/jnci/88.9.601.
12. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer. 1996;74(8):1242-7.
13. Vestey S, Perks C, Sen C, Calder C, Holly J, Winters Z. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and DCIS - implications for clinicopathology and patient outcome. Breast Cancer Res. 2004;7:R119-29. doi: 10.1186/bcr963.
14. Li X, Cao X, Li X, Zhang W, Feng Y. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci. 2007;98(10):1592-6. doi: 10.1111/ j.1349-7006.2007.00565.x.
15. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, et al. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 2008;14(3):261-7. doi: 10.1111/ j.1524-4741.2008.00572.x.
16. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, Busch C, et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol. 2005;58(4):361-6. doi: 10.1136/ jcp.2004.020834.
17. Yee D, Sharma J, Hilsenbeck SG. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst. 1994;86(23):1785-9. doi: 10.1093/jnci/ 86.23.1785.
18. Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, et al. Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol. 2007;37(8):575-82. doi: 10.1093/jjco/hym066.
19. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology. 1998;9(5):570-3. doi: 10.1097/ 00001648-199809000-00018.
20. Bruning PF, Van Doorn J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer. 1995;62(3):266-70. doi: 10.1002/ijc.2910620306.
21. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351(9113):1393-6. doi: 10.1016/ S0140-6736(97)10384-1.
22. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14(3):699-704. doi: 10.1158/1055-9965.EPI-04-0561.
23. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R, Van Gils CH, Van Noord PA, Rinaldi S, et al. Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer. 2003;106(1):90-5. doi: 10.1002/ijc.11193.
24. Gronbaek H, Flyvbjerg A, Mellemkjaer L, Tjonneland A, Christensen J, Sorensen HT, et al. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004;13(11 Pt 1):1759-64.
25. Kaulsay KK, Ng EH, Ji CY, Ho GH, Aw TC, Lee KO. Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. Eur J Endocrinol. 1999;140(2):164-8. doi: 10.1530/eje.0.1400164.
26. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-53. doi: 10.1016/S0140-6736(04)16044-3.
27. McCaig C, Perks CM, Holly JM. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: Inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci. 2002;115(Pt 22):4293-303. doi: 10.1242/jcs.00097.
28. Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet. 2006;15(1):1-10. doi: 10.1093/hmg/ddi398.
29. Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, et al. Genetic polymorphisms in the IGFBP3 gene: Association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev. 2004;13(8):1290-5.
30. Slattery ML, Sweeney C, Wolff R, Herrick J, Baumgartner K, Giuliano A, et al. Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res Treat. 2007;104(2):197-209. doi: 10.1007/s10549-006-9403-9.
31. Wagner K, Hemminki K, Israelsson E, Grzybowska E, Soderberg M, Pamula J, et al. Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer. Breast Cancer Res Treat. 2005;92(2):133-40. doi: 10.1007/ s10549-005-2417-x.
32. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: Results from the EPIC study. Br J Cancer. 2006;94(2):299-307. doi: 10.1038/sj.bjc.6602936.
33. Cheng I, Penney KL, Stram DO, Le Marchand L, Giorgi E, Haiman CA, et al. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: The multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1993-7. doi: 10.1158/1055-9965.EPI-06-0361.
34. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer. 2003;107(1):60-4. doi: 10.1002/ijc.11358.
35. Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, et al. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer. 2004;4:9. doi: 10.1186/1471-2407-4-9.
36. Garner CP, Ding YC, John EM, Ingles SA, Olopade OI, Huo D, et al. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet. 2008;123(3):247-55. doi: 10.1007/s00439-008-0468-x.
37. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005;6(10):798-808. doi: 10.1016/ S1470-2045(05)70390-9.
38. Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev. 2004;13(4):573-82.
39. dos Santos Silva I, Johnson N, De Stavola B, Torres-Mejia G, Fletcher O, Allen DS, et al. The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2006;15(3):449-55. doi: 10.1158/1055-9965.EPI-05-0555.
40. Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, et al. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: A cross-sectional study. Breast Cancer Res. 2007;9(1):R18. doi: 10.1186/bcr1655.
41. Diorio C, Brisson J, Berube S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev. 2008;17(4):880-8. doi: 10.1158/1055-9965.EPI-07-2500.
42. Stewart AJ, Johnson MD, May FE, Westley BR. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem. 1990;265(34):21172-8.
43. Lee AV, Darbre P, King RJ. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol. 1994;99(2):211-20. doi: 10.1016/0303-7207(94)90010-8.
44. Owens PC, Gill PG, De Young NJ, Weger MA, Knowles SE, Moyse KJ. Estrogen and progesterone regulate secretion of insulin-like growth factor binding proteins by human breast cancer cells. Biochem Biophys Res Commun. 1993;193(2):467-73. doi: 10.1006/bbrc.1993.1647.
45. Pratt SE, Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res. 1993;53(21):5193-8.
46. Vignon F, Bardon S, Chalbos D, Rochefort H. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J Clin Endocrinol Metab. 1993;56:1124-30.
47. Parisot JP, Leeding KS, Hu XF, DeLuise M, Zalcberg JR, Bach LA. Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line. Breast Cancer Res Treat. 1999;55(3):231-42. doi: 10.1023/A:1006274712664.
48. Milewicz T, Gregoraszczuk EL, Sztefko K, Augustowska K, Krzysiek J, Rys J. Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486). Growth Horm IGF Res. 2005;15(2):140-7. doi: 10.1016/j.ghir.2004.12.006.
49. Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U, Jepsen JS. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res. 2006;16(4):224-39. doi: 10.1016/ j.ghir.2006.06.005.
50. Lonning E, Lien EA. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Hematol. 1995;21(1-3):158-93. doi: 10.1016/ 1040-8428(94)00172-3.
51. Lonning PE, Hall K, Aakvaag A, Lien EA. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992;52(17):4719-23.
52. Pollak MN, Huynh HT, Lefebvre SP. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat. 1992;22(1):91-100. doi: 10.1007/BF01833337.
53. Gronbaek H, Tanos V, Meirow D, Peretz T, Raz I, Flyvbjerg A. Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. Anticancer Res. 2003;23(3C):2815-20.
54. Helle SI, Holly JM, Tally M, Hall K, Vander Stappen J, Lonning PE. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer. 1996;69(4):335-9. doi: 10.1002/ (SICI)1097-0215(19960822)69:4<335::AID-IJC17>3.0.CO;2-4.
55. Helle SI, Mietlowski W, Guastalla JP, Szakolczai I, Bajetta E, Sommer H, et al. Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. Eur J Cancer. 2005;41(5):694-701. doi: 10.1016/j.ejca.2004.12.015.
56. Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, et al. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins. Clin Cancer Res. 1997;3(10):1713-20.
57. Lien EA, Johannessen DC, Aakvaag A, Lonning PE. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J Steroid Biochem Mol Biol 1992;41(3-8):541-3.
58. Bajetta E, Ferrari L, Celio L, Mariani L, Miceli R, Di Leo A, et al. The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. J Steroid Biochem Mol Biol. 1997;63(4-6):261-7. doi: 10.1016/ S0960-0760(97)00120-9.
59. Reed MJ, Christodoulides A, Koistinen R, Seppala M, Teale JD, Ghilchik MW. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int J Cancer. 1992;52(2):208-12. doi: 10.1002/ ijc.2910520209.
60. Helle SI, Jonat W, Giurescu M, Ekse D, Holly JM, Lonning PE. Influence of treatment with onapristone on the IGF-system in breast cancer patients. J Steroid Biochem Mol Biol. 1998;66(3):159-63. doi: 10.1016/ S0960-0760(98)00046-6.
61. Frost VJ, Helle SI, Lonning PE, van der Stappen JW, Holly JM. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab. 1996;81(6):2216-21. doi: 10.1210/ jc.81.6.2216.
62. Perks CM, Holly JM. IGFBPs and breast cancer. Breast Dis. 2003;17:91-104.
63. James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol. 1996;58(4):395-401. doi: 10.1016/ 0960-0760(96)00048-9.
64. Towsend K, Trevino V, Falciani F, Stewart PM, Hewison M, Campbell MJ. Identification of VDR-responsive gene signatures in breast cancer cells. Oncology. 2006;71(1-2):111-23. doi: 10.1159/000100989.
65. Danforth DN Jr, Sgagias MK. Tumor necrosis factor alpha enhances secretion of transforming growth factor beta2 in MCF-7 breast cancer cells. Clin Cancer Res. 1996;2(5):827-35.
66. Koli K, Keski-Oja J. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res. 1995;55(7):1540-6.
67. Mirza MR. Anti-estrogen induced synthesis of transforming growth factor-beta in breast cancer patients. Cancer Treat Rev. 1991;18(2):145-8. doi: 10.1016/0305-7372(91)90011-N.
68. Lai LC, Erbas H, Meadows KA, Lennard TW, Holly JM. Insulin-like growth factor binding protein-3 in breast cyst fluid: Relationships with insulin-like growth factors I and II and transforming growth factor-beta 1 and 2. Cancer Lett. 1996;110(1-2):207-12. doi: 10.1016/ S0304-3835(96)04497-7.
69. McCaig C, Fowler CA, Laurence NJ, Lai T, Savage PB, Holly JM, et al. Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-beta) in normal vs cancerous breast epithelial cells. Br J Cancer. 2002;86(12):1963-9. doi: 10.1038/sj.bjc.6600355.
70. Salahifar H, Baxter RC, Martin JL. Differential regulation of insulin-like growth factor-binding protein-3 protease activity in MCF-7 breast cancer cells by estrogen and transforming growth factor-beta1. Endocrinology. 2000;141(9):3104-10. doi: 10.1210/en.141.9.3104.
71. Martin JL, Weenink SM, Baxter RC. Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogen-activated protein kinases. J Biol Chem. 2003;278(5):2969-76. doi: 10.1074/ jbc.M210739200.
72. Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: The role of altered epidermal growth factor signaling. J Clin Endocrinol Metab. 2004;89(4):1950-6. doi: 10.1210/jc.2003-030914.
73. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008;118(7):2609-19.
74. Moorehead RA, Hojilla CV, De Belle I, Wood GA, Fata JE, Adamson ED, et al. Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J Biol Chem. 2003;278(50):50422-7. doi: 10.1074/ jbc.M306894200.
75. Perks CM, Vernon EG, Rosendahl AH, Tonge D, Holly JM. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene. 2007;26(40):5966-72. doi: 10.1038/sj.onc.1210397.
76. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A. 2007;104(13):5563-8. doi: 10.1073/ pnas.0609139104.
77. Frommer KW, Reichenmiller K, Schutt BS, Hoeflich A, Ranke MB, Dodt G, et al. IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol. 2006;37(1):13-23. doi: 10.1677/ jme.1.01955.
78. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A. 1999;96(6):3149-53. doi: 10.1073/pnas.96.6.3149.
79. Busby WH Jr, Nam TJ, Moralez A, Smith C, Jennings M, Clemmons DR. The complement component C1s is the protease that accounts for cleavage of insulin-like growth factor-binding protein-5 in fibroblast medium. J Biol Chem. 2000;275(48):37638-44. doi: 10.1074/jbc.M006107200.
80. Mohan S, Thompson GR, Amaar YG, Hathaway G, Tschesche H, Baylink DJ. ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry. 2002;41(51):15394-403. doi: 10.1021/bi026458q.
81. Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem. 2001;276(24):21849-53. doi: 10.1074/jbc.M102191200.
82. Hsieh ML, Charlesworth MC, Goodmanson M, Zhang S, Seay T, Klee GG, et al. Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res. 1997;57(13):2651-6.
83. Magklara A, Scorilas A, Lopez-Otin C, Vizoso F, Ruibal A, Diamandis EP. Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid. Clin Chem. 1999;45(10):1774-80.
84. Diamandis EP. Prostate specific antigen - new applications in breast and other cancers. Anticancer Res. 1996;16(6C):3983-4.
85. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996;40(2):171-8. doi: 10.1007/BF01806212.
86. Paliouras M, Diamandis EP. Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Res Treat. 2007;102(1):7-18. doi: 10.1007/ s10549-006-9312-y.
87. Paliouras M, Diamandis EP. Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression. Tumour Biol. 2008;29(2):63-75. doi: 10.1159/000135686.
88. Ewan King L, Li X, Cheikh Saad Bouh K, Pedneault M, Chu CW. Human kallikrein 10 ELISA development and validation in breast cancer sera. Clin Biochem. 2007;40(13-14):1057-62. doi: 10.1016/ j.clinbiochem.2007.05.008.
89. Rehault S, Monget P, Mazerbourg S, Tremblay R, Gutman N, Gauthier F, et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem. 2001;268(10):2960-8. doi: 10.1046/j.1432-1327.2001.02185.x.
90. Yu H, Berkel H. Prostate-specific antigen (PSA) in women. J La State Med Soc. 1999;151(4):209-13.
91. Narita D, Anghel A, Motoc M. Prostate-specific antigen may serve as a pathological predictor in breast cancer. Rom J Morphol Embryol. 2008;49(2):173-80.
92. Sauter ER, Daly M, Linahan K, Ehya H, Engstrom PF, Bonney G, et al. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1996;5(12):967-70.
93. Radowicki S, Kunicki M, Bandurska-Stankiewicz E. Prostate-specific antigen in the serum of women with benign breast disease. Eur J Obstet Gynecol Reprod Biol. 2008;138(2):212-6. doi: 10.1016/ j.ejogrb.2007.05.023.
94. Sauter ER, Chervoneva I, Diamandis A, Khosravi JM, Litwin S, Diamandis EP. Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer. Cancer Detect Prev. 2002;26(2):149-57. doi: 10.1016/ S0361-090X(02)00028-4.
95. Narita D, Cimpean AM, Anghel A, Raica M. Prostate-specific antigen value as a marker in breast cancer. Neoplasma. 2006;53(2):161-7. 161-7.
96. Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura T, et al. Correlation of prostate-specific antigen promoter polymorphisms with clinicopathological characteristics in breast cancer. Anticancer Res. 2002;22(3):1825-8.
97. Look MP, Foekens JA. Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS. 1999;107(1):150-9.
98. Descotes F, Ville G, Bobin JY, Barbier Y, Saez S. Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas. Breast Cancer Res Treat. 1998;49(2):135-43. doi: 10.1023/A:1006015529564.
99. Hurd TC, Sait S, Kohga S, Winston J, Martinick M, Saxena R, et al. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ. Ann Surg Oncol. 2007;14(11):3117-24. doi: 10.1245/ s10434-007-9529-y.
100. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, et al. uPA and PAI-1 in breast cancer: Review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem. 2008;45:31-45. doi: 10.1016/S0065-2423(07)00002-9.
101. Tyndall JD, Kelso MJ, Clingan P, Ranson M. Peptides and small molecules targeting the plasminogen activation system: Towards prophylactic anti-metastasis drugs for breast cancer. Recent Patents Anticancer Drug Discov 2008;3(1):1-13.
102. Campbell PG, Durham SK, Suwanichkul A, Hayes JD, Powell DR. Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3. Am J Physiol. 1998;275(2 Pt 1):E321-31.
103. Campbell PG, Andress DL. Plasmin degradation of insulin-like growth factor-binding protein-5 (IGFBP-5): Regulation by IGFBP-5-(201-218). Am J Physiol. 1997;273(5 Pt 1):E996-1004.
104. Nam TJ, Busby W Jr, Clemmons DR. Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I. Endocrinology. 1997;138(7):2972-8. doi: 10.1210/en.138.7.2972.
105. Sorrell AM, Shand JH, Tonner E, Gamberoni M, Accorsi PA, Beattie J, et al. Insulin-like growth factor binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I or heparin. J Biol Chem. 2006;281:10883-9.
106. Lalou C, Lassarre C, Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology. 1996;137(8):3206-12. doi: 10.1210/en.137.8.3206.
107. Rochefort H, Capony F, Garcia M. Cathepsin D: A protease involved in breast cancer metastasis. Cancer Metastasis Rev. 1990;9(4):321-31. doi: 10.1007/BF00049522.
108. De Leon DD, Issa N, Nainani S, Asmerom Y. Reversal of cathepsin D routing modulation in MCF-7 breast cancer cells expressing antisense insulin-like growth factor II (IGF-II). Horm Metab Res. 1999;31(2-3):142-7. doi: 10.1055/s-2007-978712.
109. Mathieu M, Rochefort H, Barenton B, Prebois C, Vignon F. Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/ mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinol. 1990;4(9):1327-35.
110. Cappelletti V, Fioravanti L, Miodini P, Di Fronzo G. Modulation of cathepsin-D and pS2 protein levels in human breast cancer cell lines. Tumour Biol. 1996;17(5):290-8.
111. Conover CA. Insulin-like growth factor binding protein proteolysis in bone cell models. Prog Growth Factor Res. 1995;6(2-4):301-9. doi: 10.1016/0955-2235(95)00032-1.
112. Coverley JA, Baxter RC. Phosphorylation of insulin-like growth factor binding proteins. Mol Cell Endocrinol. 1997;128(1-2):1-5. doi: 10.1016/ S0303-7207(97)04032-X.
113. Jones JI, D'Ercole AJ, Camacho-Hubner C, Clemmons DR. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: Effects on affinity for IGF-I. Proc Natl Acad Sci U S A. 1991;88(17):7481-5. doi: 10.1073/pnas.88.17.7481.
114. Coverley JA, Martin JL, Baxter RC. The effect of phosphorylation by casein kinase 2 on the activity of insulin-like growth factor-binding protein-3. Endocrinology. 2000;141(2):564-70. doi: 10.1210/en.141.2.564.
115. Martin JL, Coverley JA, Pattison ST, Baxter RC. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology. 1995;136(3):1219-26. doi: 10.1210/en.136.3.1219.
116. Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, et al. Insulin-like growth factor binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology. 2006;147:2112-21.
117. Schedlich LJ, Nilsen T, John AP, Jans DA, Baxter RC. Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology. 2003;144(5):1984-93. doi: 10.1210/ en.2002-220798.
118. Conover CA. Glycosylation of insulin-like growth factor binding protein-3 (IGFBP-3) is not required for potentiation of IGF-I action: evidence for processing of cell-bound IGFBP-3. Endocrinology. 1991;129(6):3259-68.
119. Jones JI, Gockerman A, Busby WH Jr, Camacho-Hubner C, Clemmons DR. Extracellular matrix contains insulin-like growth factor binding protein-5: Potentiation of the effects of IGF-I. J Cell Biol. 1993;121(3):679-87. doi: 10.1083/jcb.121.3.679.
120. Clemmons DR. IGF binding proteins: Regulation of cellular actions. Growth Regul. 1992;2(2):80-7.
121. Rechler MM. Insulin-like growth factor binding proteins. Vitam Horm. 1993;47:1-114. doi: 10.1016/S0083-6729(08)60444-6.
122. Bach LA, Thotakura NR, Rechler MM. Human insulin-like growth factor binding protein-6 is O-glycosylated. Growth Regul. 1993;3(1):59-62.
123. Firth SM, Baxter RC. The role of glycosylation in the action of IGFBP-3. Prog Growth Factor Res. 1995;6(2-4):223-9. doi: 10.1016/ 0955-2235(95)00009-7.
124. Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM. A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells. Biochem Biophys Res Commun. 2002;294(5):988-94. doi: 10.1016/ S0006-291X(02)00569-7.
125. Firth SM, Baxter RC. Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J Endocrinol. 1999;160(3):379-87. doi: 10.1677/joe.0.1600379.
126. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev. 1995;16(1):3-34. doi: 10.1210/ er.16.1.3.
127. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MB, Bierich JR. Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I. Endocrinology. 1989;125(2):766-72.
128. Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun. 1997;237(3):690-3. doi: 10.1006/bbrc.1997.7089.
129. Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res. 2006;66(14):7245-52. doi: 10.1158/0008-5472.CAN-05-3555.
130. Firth SM, Fanayan S, Benn D, Baxter RC. Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. Biochem Biophys Res Commun. 1998;246(2):325-9. doi: 10.1006/bbrc.1998.8615.
131. Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol. 1993;157(2):229-36. doi: 10.1002/jcp.1041570204.
132. McGuire WL Jr, Jackson JG, Figueroa JA, Shimasaki S, Powell DR, Yee D. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: Use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst. 1992;84(17):1336-41. doi: 10.1093/jnci/84.17.1336.
133. Yee D, Jackson JG, Kozelsky TW, Figueroa JA. Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells. Cell Growth Differ. 1994;5(1):73-7.
134. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem. 2000;275(50):39174-81. doi: 10.1074/ jbc.M908888199.
135. Collard TJ, Guy M, Butt AJ, Perks CM, Holly JM, Paraskeva C, et al. Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis
136. Gill ZP, Perks CM, Newcomb PV, Holly JM. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem. 1997;272(41):25602-7. doi: 10.1074/jbc.272.41.25602.
137. Fowler CA, Perks CM, Newcomb PV, Savage PB, Farndon JR, Holly JM. Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int J Cancer. 2000;88(3):448-53. doi: 10.1002/ 1097-0215(20001101)88:3<448::AID-IJC18>3.0.CO;2-V.
138. Perks CM, McCaig C, Holly JM. Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria. J Cell Biochem. 2000;80(2):248-58. doi: 10.1002/ 1097-4644(20010201)80:2<248::AID-JCB140>3.0.CO;2-4.
139. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 1995;377(6550):646-9. doi: 10.1038/377646a0.
140. Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D, Holly JM. IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer. 2000;88(3):336-41. doi: 10.1002/ 1097-0215(20001101)88:3<336::AID-IJC3>3.0.CO;2-A.
141. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM, et al. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res. 2000;60(1):22-7.
142. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J Cell Biochem. 1999;75(4):652-64. doi: 10.1002/ (SICI)1097-4644(19991215)75:4<652::AID-JCB11>3.0.CO;2-0.
143. Butt AJ, Dickson KA, Jambazov S, Baxter RC. Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology. 2005;146(7):3113-22. doi: 10.1210/ en.2004-1408.
144. Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM. Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cells. Biochem Biophys Res Commun. 2002;294(5):995-1000. doi: 10.1016/ S0006-291X(02)00570-3.
145. Martin JL, Jambazov S. Insulin-like growth factor binding protein-3 in extracellular matrix stimulates adhesion of breast epithelial cells and activation of p44/42 mitogen-activated protein kinase. Endocrinology. 2006;147(9):4400-9. doi: 10.1210/en.2006-0094.
146. Perks CM, Newcomb PV, Norman MR, Holly JM. Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells. J Mol Endocrinol. 1999;22(2):141-50. doi: 10.1677/jme.0.0220141.
147. Schutt B, Langkamp M, Ranke M, Elmlinger M. Intracellular signalling of insulin-like growth factor binding protein-2. Growth Horm IGF Res. 2000;10:A30. Abstract 35.
148. Irving JA, Lala PK. Functional role of cell surface integrins on human trophoblast cell migration: Regulation by TGF-beta, IGF-II, and IGFBP-1. Exp Cell Res. 1995;217(2):419-27. doi: 10.1006/excr.1995.1105.
149. Jones JI, Doerr ME, Clemmons DR. Cell migration: Interactions among integrins, IGFs and IGFBPs. Prog Growth Factor Res. 1995;6(2-4):319-27. doi: 10.1016/0955-2235(95)00015-1.
150. Clemmons DR, Busby WH, Arai T, Nam TJ, Clarke JB, Jones JI, et al. Role of insulin-like growth factor binding proteins in the control of IGF actions. Prog Growth Factor Res. 1995;6(2-4):357-66. doi: 10.1016/ 0955-2235(95)00013-5.
151. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci U S A. 1993;90(22):10553-7. doi: 10.1073/pnas.90.22.10553.
152. Kiepe D, Van Der Pas A, Ciarmatori S, Standker L, Schutt B, Hoeflich A, et al. Defined carboxy-terminal fragments of insulin-like growth factor (IGF) binding protein-2 exert similar mitogenic activity on cultured rat growth plate chondrocytes as IGF-I. Endocrinology. 2008;149(10):4901-11. doi: 10.1210/en.2007-1395.
153. Andress DL. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am J Physiol. 1998;274(4 Pt 1):E744-50.
154. Oh Y, Muller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem. 1993;268(35):26045-8.
155. Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem. 1997;272(33):20572-6. doi: 10.1074/ jbc.272.33.20572. 20572-6.
156. Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA, et al. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology. 2006;147(7):3484-500. doi: 10.1210/ en.2006-0005.
157. Gui Y, Murphy LJ. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): Demonstration of IGF-I/IGFBP-3/fn ternary complexes in human plasma. J Clin Endocrinol Metab. 2001;86(5):2104-10. doi: 10.1210/jc.86.5.2104.
158. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ. ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem. 2000;275(24):18574-80. doi: 10.1074/ jbc.M002172200.
159. Nam TJ, Busby WH Jr, Rees C, Clemmons DR. Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology. 2000;141(3):1100-6.
160. Singh B, Charkowicz D, Mascarenhas D. Insulin-like growth factor-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3. J Biol Chem. 2004;279(1):477-87. doi: 10.1074/jbc.M307322200.
161. Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst. 2004;96(20):1536-48.
162. McCaig C, Perks C, Holly J. MAP Kinase inhibitor blocks IGF-independent effect of IGFBP-3 on breast epithelial cell survival and cell attachment. Proceedings of the Endocrine Society's 83rd Annual Meeting 2001;P2:268.
163. McCaig C, Perks CM, Holly JM. Signalling pathways involved in the direct effects of IGFBP-5 on breast epithelial cell attachment and survival. J Cell Biochem. 2002;84(4):784-94. doi: 10.1002/jcb.10093.
164. Firth SM, Ganeshprasad U, Baxter RC. Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3. J Biol Chem. 1998;273(5):2631-8. doi: 10.1074/jbc.273.5.2631.
165. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: Kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology. 1999;140(3):1319-28. doi: 10.1210/en.140.3.1319.
166. Hollowood AD, Stewart CE, Perks CM, Pell JM, Lai T, Alderson D, et al. Evidence implicating a mid-region sequence of IGFBP-3 in its specific IGF-independent actions. J Cell Biochem. 2002;86(3):583-9. doi: 10.1002/ jcb.10223.
167. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem. 1998;273(29):18347-52. doi: 10.1074/jbc.273.29.18347.
168. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem. 2000;275(43):33607-13. doi: 10.1074/jbc.M002547200.
169. Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J Biol Chem. 2005;280(17):16942-8. doi: 10.1074/jbc.M412757200.
170. Zappala G, Elbi C, Edwards J, Gorenstein J, Rechler MM, Bhattacharyya N. Induction of apoptosis in human prostate cancer cells by insulin-like growth factor binding protein-3 does not require binding to retinoid X receptor-alpha. Endocrinology. 2008;149(4):1802-12. doi: 10.1210/ en.2007-1315.
171. Bhattacharyya N, Pechhold K, Shahjee H, Zappala G, Elbi C, Raaka B, et al. Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J Biol Chem. 2006;281(34):24588-601. doi: 10.1074/jbc.M509463200.
172. Jurgeit A, Berlato C, Obrist P, Ploner C, Massoner P, Schmolzer J, et al. Insulin-like growth factor-binding protein-5 enters vesicular structures but not the nucleus. Traffic. 2007;8(12):1815-28. doi: 10.1111/j.1600-0854.2007.00655.x.
173. Fanayan S, Firth SM, Butt AJ, Baxter RC. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor. J Biol Chem. 2000;275(50):39146-51. doi: 10.1074/ jbc.M006964200.
174. Fu P, Thompson JA, Bach LA. Promotion of cancer cell migration: An insulin-like growth factor (IGF)-independent action of IGF-binding protein-6. J Biol Chem. 2007;282(31):22298-306. doi: 10.1074/ jbc.M703066200.
175. Yu Q, Banerjee K, Paterson J, Alami N, Shiry L, Leyland-Jones B. Insulin-like growth factor binding protein-3: Single-agent and synergistic effects with chemotherapeutic drugs on solid tumor models. In: Proceedings of the AACR, Abstract 755, Washington DC; 2003. p. 172.
176. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression. Eur J Cancer. 2002;38(18):2362-70. doi: 10.1016/ S0959-8049(02)00210-1.
177. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A. 2007;104(41):16158-63. doi: 10.1073/pnas.0702596104.
178. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002;1(9):707-17.
179. Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, et al. An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Res. 2008;68(12):4893-901. doi: 10.1158/0008-5472.CAN-07-6726.
180. Zhang X, Yee D. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res. 2002;62(15):4369-75.
181. Subramanian A, Sharma AK, Banerjee D, Jiang WG, Mokbel K. Evidence for a tumour suppressive function of IGF1-binding proteins in human breast cancer. Anticancer Res. 2007;27(5B):3513-8.